Back to compounds

COMPOUND PROFILE / PEPTIDES & ANALOGUES

Eloralintide.

Research draft

Eloralintide is a selective long-acting amylin receptor agonist investigated for obesity.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Overview

Eloralintide is a selective long-acting amylin receptor agonist investigated for obesity.

CLASSIFICATIONPeptides & analogues
MOLECULAR / SEQUENCE INFONot specified
PRIMARY CONTEXTCompound

Mechanism

It engages amylin-mediated satiety pathways.

Human research

Early human proof-of-concept studies exist. Findings from combination trials with tirzepatide must remain separate.

Preclinical & other research

Discovery work characterised receptor activity and metabolic effects.

Safety & unknowns

Gastrointestinal tolerability and longer-term outcomes remain important.

Regulatory status

Investigational in reviewed sources; monotherapy and combination products require separate assessment.

Reported use & evidence

Research profile draft

The supplied Eloralintide profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Explore more compounds